Table 1

Risk for all cancers*

Analysis time	Antibody	Subtype	Sample size	Person-years	No. observed	No. expected	SIR (95% CI)	P value
Overall risk	All	Limited	1470	26 624	128	182.0	0.70 (0.59 to 0.84)	<0.001†
		Diffuse	913	11 062	77	69.0	1.12 (0.88 to 1.39)	0.36
	Cenp	Limited	570	11 857	53	90.0	0.59 (0.44 to 0.77)	<0.001†
		Diffuse	38	754	3	5.5	0.55 (0.11 to 1.60)	0.41
	Topo	Limited	241	4035	20	25.5	0.78 (0.48 to 1.21)	0.32
		Diffuse	240	3134	17	17.7	0.96 (0.56 to 1.53)	0.99
	Pol III	Limited	59	962	9	6.8	1.33 (0.61 to 2.53)	0.48
		Diffuse	219	2509	36	17.6	2.05 (1.44 to 2.84)	<0.001†
	CTP-negative	Limited	242	4065	31	25.5	1.21 (0.82 to 1.72)	0.33
		Diffuse	137	1709	8	10.6	0.75 (0.32 to 1.48)	0.53
±3 years	All	Limited	1470	7935	35	41.4	0.84 (0.59 to 1.18)	0.36
		Diffuse	913	5210	44	28.2	1.56 (1.13 to 2.10)	0.007
	Cenp	Limited	570	3003	10	16.7	0.60 (0.29 to 1.10)	0.111
		Diffuse	38	212	0	1.1	0.00 (0.00 to 3.34)	0.66
	Topo	Limited	241	1353	4	6.6	0.60 (0.16 to 1.54)	0.42
		Diffuse	240	1393	10	6.4	1.55 (0.75 to 2.86)	0.23
	Pol III	Limited	59	305	3	1.9	1.59 (0.33 to 4.66)	0.58
		Diffuse	219	1209	25	8.0	3.13 (2.03 to 4.62)	<0.001†
	CTP-negative	Limited	242	1335	15	6.2	2.43 (1.36 to 4.00)	0.004†
		Diffuse	137	808	4	4.2	0.95 (0.26 to 2.44)	0.99

*Excluding non-melanoma skin cancers.
†Statistically significant P value after adjustment for multiple (10) comparisons per analysis.
cenp, centromere; CTP, centromere, topoisomerase-1 and RNA polymerase III; pol, polymerase; topo, topoisomerase-1.